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Abstract 
Background: Although increased serum IgG4 level and tissue infiltration of IgG4-positive 
cells are key events in IgG4-related disease (IgG4RD), and nearly half of IgG4RD 
patients show hypocomplementemia, the role of IgG4 in the pathogenesis of IgG4RD 
remains unclear. Many reports show that altered IgG glycosylation, especially IgG with 
agalactosylated N-linked glycan (G0 N-glycan), have proinflammatory roles including 
complement activation, implicated in the pathogenesis of various inflammatory diseases. 
This study determined the concentration of N-linked glycans (N-glycan) released from 
serum IgG4 in IgG4RD patients and compared the difference of glycosylation changes to 
those in healthy controls. We also compared the concentration of each IgG4 glycoform 
between patients with and without hypocomplementemia and individual organ 
involvement (kidney, pancreas, lymph node) in IgG4RD. 
Methods: We collected sera from 12 IgG4RD patients and 8 healthy controls. IgG4 was 
isolated from sera via Melon™ Gel IgG Spin Purification Kit followed by Capture Select 
IgG4 (Hu) Affinity Matrix. IgG4 N-glycans were analyzed by S-BIO GlycanMap® 
Xpress methodology. 
Results: Significant increases of IgG4 G0 N-glycan and IgG4 fucosylated N-glycan (F1 
N-glycan) concentrations were observed in IgG4RD compared with healthy controls. 
Although we observed decreased levels of IgG4 F0 glycan in IgG4RD with 
hypocomplementemia, there were no significant differences in the galactosylation and 
sialyation of IgG4 N-glycans. Furthermore, there were no significant differences in the 
glycosylation of IgG4 N-glycans between patients with and without individual organ 
involvement of IgG4RD. 
Conclusions: Although IgG4 has anti-inflammatory properties, IgG4 G0 and F1 glycans 
were increased in patients with IgG4RD. Our results suggest that decreased 
galactosylation of IgG4 is not related to complement activation and the differences of 
individual organ involvement in IgG4RD. IgG4 fucosylation change may be related to 
complement activation in IgG4RD. Further investigation is needed to clarify the role of 
IgG4 in IgG4RD. 
 
 
 
 
 
 
 
Introduction  
IgG4-related disease (IgG4RD) is an emerging clinical disorder characterized by 
increased serum IgG4 concentrations, dense lymphoplasmacytic infiltrate, IgG4-positive 
plasma cells, and storiform fibrosis [1, 2]. IgG4RD includes various diseases formerly 
diagnosed as Mikulicz's Disease [3, 4], autoimmune pancreatitis [5, 6], retroperitoneal 
fibrosis [7, 8], tubulointerstitial nephritis [9-11], Riedel’s thyroiditis [12], and 
inflammatory pseudotumor [13]. Although elevated serum IgG4 levels and infiltration of 
IgG4-plasma cells in tissues are observed, much remains unknown about the role of IgG4 
in the pathogenesis of IgG4RD. 
Among the subclasses of IgG, IgG4 is the least abundant subclass in human 
serum. IgG4 is distinguished from other IgG subclasses by its unique functional and 
structural properties. IgG4 lacks the ability to activate the classical complement pathway 
because of reduced binding capacity to complement component 1q (C1q)[14-17]. IgG4 
also has a low binding capacity for Fcγ receptors (FcγRs)[18] and can exchange half its 
molecules in vivo to form antibodies with two different binding specificities that are 
monovalent [19].  
 Although IgG4 itself does not activate the classical complement pathway 
because of a low C1q binding capacity, nearly half of IgG4RD patients show 
hypocomplementemia[11, 20]. Several reports showed the association of immune 
complexes (ICs) containing IgG1 with hypocomplementemia, and suggested that 
complement activation in IgG4RD is caused by ICs containing IgG1, 2, 3, and IgM, but 
not IgG4, via the classical pathway[20-22]. However, our previous report showed IC 
containing IgG4 and IgM, isolated from IgG4RD patients with hypocomplementemia, 
activated the complement system via the classical pathway as well as the lectin 
pathway[23]. Thus, the mechanism and the role of IgG4 in complement activation in 
IgG4RD remains unclear. 
Protein glycosylation is a post-translational modification affecting the structures 
and functions of many proteins required for normal immune function. Over the past 
decades, many studies have investigated the structural and biological roles of 
immunoglobulin G (IgG) glycosylation. In IgG molecules, two N-glycans are linked to 
heavy chains at asparagine (Asn) residues (CH2–84.4) in the CH2 domain of the Fc 
portion[24, 25]. Fc-linked glycans exhibit complex-type bi-antennary N-glycans with a 
high content of core fucose and a variable number of galactose residues leading to the 
major glycoforms G0 (agalactosylated), G1 (monogalactosylated), and G2 
(digalactosylated). Some populations of Fc-linked glycans contain bisection GlcNAc 
and/or terminal sialic acids. 
Recent studies revealed that IgG glycosylation, especially the degree of 
galactosylation, is associated with various physiological and pathological conditions[26]. 
Clinically, increased levels of serum IgG with G0 glycan were observed in patients with 
rheumatoid arthritis (RA), Crohn’s disease, systemic lupus erythematosus, or 
granulomatosis with polyangiitis (GPA, formerly named Wegener’s granulomatosis) [27-
29], and elevated levels of IgG with G0 glycans were also correlated with RA disease 
activity [30]. Furthermore, the lack of core-fucose or the presence of bisecting GlcNAc 
improved the affinity of Fc binding to FcγR IIIa, resulting in increased antibody-
dependent cellular cytotoxicity[31-33]. It was also reported that a lack of sialic acid and 
low levels of galactosylation promoted proinflammatory functions[34-36]. Interestingly, 
agalactosylated IgG binds to mannose-binding protein (MBL) in serum and activates the 
lectin complement pathway, which participates in the pathogenesis of RA[37, 38]. 
Although recent studies revealed the importance of altered IgG glycosylation in 
the pathogenesis of various autoimmune and inflammatory diseases, little is known about 
the glycosylation of IgG4 in IgG4RD. In this study, we determined the occurrence (%) 
and absolute concentration of each glycoform released from IgG4 isolated from the sera 
of IgG4RD patients and healthy controls. We also compared the differences of 
glycosylation changes between patients with IgG4RD and healthy controls. The 
occurrence (%) and absolute concentration of each glycoform released from IgG4 isolated 
from the sera of IgG4RD patients were compared between patients with and without 
hypocomplementemia and individual organ involvement (kidney, pancreas, lymph node) 
for galactosylation, fucosylation, and sialyation in IgG4RD. 
 
Materials and Methods 
Patients and blood samples 
Overall, 12 patients with IgG4 related disease (IgG4RD) who fulfilled the 
comprehensive diagnostic criteria for IgG4RD[1] and 8 healthy controls were included in 
this study. Patient demographics are summarized in Table 1. Sera were separated from the 
blood samples and stored at −80°C until further analysis. Written informed consent was 
obtained from the patients, next of kin or legally authorized guardians. This study, 
including the process of securing informed consent, was approved by the ethics 
Committee of Fukushima Medical University (approval number 1722), which is guided 
by local policy, national law, and the World Medical Association Declaration of Helsinki. 
 
 
 
Table 1. Clinical characteristics of patients. M, male; F, female; N.D., not done; LN, 
lymph node  
 
Patient Age/Gender IgG4 (mg/dl) C3/C4 (mg/dl) CH50 Involvement of organs 
1 69/M 768 49/2 <5 Kidney, Pancreas, LN 
2 77/F 1160 20/1 <5 Submandibular gland, LN, Lung 
3 62/M 1160 59/3 <12 LN, Retroperitoneal fibrosis 
4 50/M 2630 37/1 N.D. LN 
5 65/M 297 35/1 <12 Kidney, Pancreas, Sclerosing 
cholangitis 
6 60/M 670 21/2 <12 Kidney, Submandibular gland, LN 
7 64/F 1020 22/0.7 7 Kidney 
8 60/M 480 120/38 64.8 Pancreas 
9 48/F 108 105/34 40.5 Pancreas 
10 64/M 945 107/18 41 Submandibular gland, 
Retroperitoneal fibrosis, Kidney  
11 72/M 289 82/18 35 Lung 
12 53/M 1040 131/42 54 Submandibular gland, LN, Lung, 
Kidney 
 
Isolation of IgG from patient sera 
IgG was isolated using the Melon™ Gel IgG Spin Purification Kit (Thermo 
Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. 
Briefly, serum was dialyzed with Melon™ Gel purification buffer, and mixed with 20% 
slurry gel in a spin column. After end-over-end mixing for 5 min at room temperature 
(RT), the spin column was centrifuged at 5,000 ×g for 1 min to collect purified IgG. The 
concentration of purified IgG was measured by absorbance at 280 nm using an extinction 
coefficient (E2800.1%) of 1.4.  
Isolation of IgG4 
IgG4 was isolated via Capture Select IgG4 (Hu) Affinity Matrix (Life 
Technologies, Paisley, UK) according to the manufacturer’s instructions. Briefly, purified 
IgG was loaded onto a 2 ml Capture Select IgG4 column in fully preserved PBS. Then, 
the column was eluted with 0.1 M glycine-HCl buffer (pH 2.8). The eluted IgG4 fractions 
were neutralized with 1/10 volume Tris-HCl (pH 9.0). Purified IgG4 was immediately 
buffer exchanged in ddH2O, then concentrated using Amicon ultra-0.5 ml (Ultracel®-3K) 
(EMD Millipore, Billerica, MA, USA). Protein concentrations were determined using the 
Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc. Hercules, CA, USA). IgG4 purities 
were established by SDS-PAGE and western blotting. 
Analyzation of isolated IgG4 purity for IgG subclass 
composition by western blotting 
Isolated IgG4 were analyzed by western blotting assays for IgG subclass 
composition. Isolated IgG4 were resuspended in non-reduced sample buffer, subjected to 
10% SDS-PAGE, and electrophoretically transferred onto a polyvinylidene difluoride 
(PVDF) membrane. After incubation with blocking buffer, the membrane was incubated 
separately with biotinylated monoclonal anti-human IgG subclass 1–4 (BD Bioscience, 
Franklin Lakes, NJ, USA) diluted at 1:1000 in blocking buffer. After incubation at 4°C 
overnight, the membrane was washed with PBS-T, incubated with Vectastain ABC 
Reagent (Vector Laboratories, Inc., Burlingame, CA, USA) for 30 min at RT, and 
subsequently developed with 3,3′-diaminobenzidine tetrahydrochloride. The color of the 
image was converted from brown to black by computer. 
Glycomic analysis of isolated IgG4 
 Each sample was analyzed to quantitate N-linked glycans using S-BIO 
proprietary GlycanMap® Xpress methodology based on methods previously reported[39-
41]. Several control samples were also analyzed to assess linearity, repeatability, 
sensitivity, and accuracy. After transferring aliquots of each sample to a 96-well plate and 
adding internal standards to aid quantitation, samples were denatured, digested with 
trypsin, and heat-inactivated. N-glycans were then released with PNGase F (New England 
Biolabs, Ipswich, Massachusetts, USA) and captured chemoselectively on BlotGlyco® 
beads (Sumitomo Bakelite Co. Ltd., Tokyo, Japan), followed by methyl esterification of 
the sialic acid residues for stabilization of the mass spectrometric analysis. Finally, 
glycans were released from the beads, simultaneously labeled, and spotted onto a MALDI 
target plate. All processes from initial aliquoting to spotting on the MALDI plate were 
fully automated, using 96-well format robotic technology. 
 MALDI-TOF mass spectrometry (MS) analysis was performed on an ultraflex 
III mass spectrometer (Bruker Daltonics, Yokohama, Japan) in the positive-ion, reflectron 
mode using S-BIO proprietary matrix composition. Each sample was spotted in 
quadruplicate, and spectra were obtained in an automated manner using the AutoXecute 
feature in flexControl software (Bruker Daltonics, Yokohama, Japan). 
Resulting mass spectra were analyzed using S-BIO proprietary bioinformatic 
programs, which correct for mass differences induced by the chemical derivatization 
inherent in the GlycanMap® Xpress assay. 
 Glycan compositions were assigned to each peak based on m/z. The intensities 
from each of the four quadruplicated spectra were normalized to that of an internal 
standard with a known concentration and averaged. Data were also corrected for the 
inherent decrease in peak intensity as m/z increases in mass spectrometric measurements, 
yielding absolute concentrations that are comparable to those created by 
HPLC/fluorescent methods. Glycans representing less than 0.5% of the total glycan 
concentration were not reported.  
 Glycan compositions were shown as a code of five digit. The code represents the 
number of hexose (Galactose (Gal), Mannose (Man), or Glucose (Glc)), N-
acetylhexosamine (N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc)), 
deoxyhexose (Fucose (Fuc)), N-acetylneuraminic acid (N-acetylneuraminic acid 
(Neu5Ac)), and N-glycolylneuraminic acid (N-glycolylneuraminic acid (Neu5Gc)) 
residues. 
Statistical analysis  
Statistical analysis was performed using the Mann-Whitney U-test for the 
comparison of median values. Statistical analyses were performed using SPSS software, 
version 22 (IBM SPSS, Armonk, NY). P values less than 0.05 were considered 
statistically significant. 
 
Results 
Purity of IgG4 isolated from sera of IgG4-related disease 
patients 
 The purity of IgG4 isolated from the sera of patients with IgG4RD was 
confirmed by SDS-PAGE and western blot analysis. We did not observe protein 
contamination by SDS-PAGE (Fig 1A) (S1 Fig). Blot reactivity was only observed for 
anti-IgG4 antibody to isolated IgG4 from the sera of IgG4RD patients (Fig 1B) (S2-S5 
Fig). 
 
 Fig 1. IgG4 isolated from the sera of patients with IgG4-related disease. (A) SDS-
PAGE (under nonreducing condition) analysis of isolated IgG4. Bands of marker proteins 
over 75 kDa are blurry and unclear. (B) Western blot analysis of anti-IgG subclasses 
reacting with isolated IgG4. Blot reactivities for anti IgG4 antibody were observed in all 
samples. M and P are abbreviations for a marker of molecular weight and positive control, 
respectively. Number 1 through 12 are equivalent to patient number of Table 1. 
 
Characterization of glycans of IgG4 
We detected 23 glycans released from isolated IgG4 (S1 Data). Proposed 
structures for all 23 glycans and the code used are shown in Fig 2. Four glycans were 
agalactosylated (G0), 7 glycans were monogalactosylated (G1), 10 glycans were 
digalactosylated (G2), and 2 glycans were trigalactosylated (G3). Fourteen glycans were 
fucosylated (F1), and 9 glycans were afucosylated (F0). Eleven glycans were asialylated 
(S0), 8 glycans were monosialylated (S1), and 4 glycans were disialylated (S2). Seven 
glycans had a bisecting arm (B1), and 17 glycans did not (B0).  
 
 
Fig 2. Glycan codes and proposed structures for 23 glycans detected in this study. 
 
 
 
Occurrence of each glycan group (G0, G1, G2, G3, F0, F1, S0, 
S1, S2, B0, B1) released from IgG4 isolated from the sera of 
patients with IgG4-related disease and healthy controls 
Results are expressed as the percentage of each glycan group released from IgG4 
isolated from the sera of IgG4RD patients and healthy controls. As shown in Table 2, no 
significant differences in the percentage of each glycan group (G0, G1, G2, G3, F0, F1, 
S0, S1, S2, B0, B1) were observed when IgG4RD and healthy controls were compared. 
 
Table 2. Occurrence of each glycan group released from IgG4. IgG4RD, IgG4-related 
disease; NS, not significant. 
 IgG4RD (n=12) 
Median (range) 
Healthy control (n=8) 
Median (range) 
p value 
G0 (%) 36.3 (30.7 – 48.2) 35.3 (19.9 – 48.7) NS 
G1 (%) 23.8 (21.6 – 27.2) 27.2 (23.3 – 30.3) NS 
G2 (%) 38.2 (27.7– 45.5) 37.3 (28.0 – 51.1) NS 
G3 (%) 0.5 (0.0 – 1.1) 0.0 (0.0) NS 
F0 (%) 3.7 (2.0 – 9.6)) 6.5 (2.9 – 8.1) NS 
F1 (%) 96.3 (90.4 – 98.0) 93.6 (91.9 – 97.1) NS 
S0 (%) 61.8 (52.8 – 69.7) 67.6 (59.5 – 72.2) NS 
S1 (%) 23.3 (19.5 – 27.5) 20.7 (17.3 – 23.3) NS 
S2 (%) 14.6 (10.7 – 21.2) 11.7 (9.5 – 17.2) NS 
B0 (%) 75.6 (68.3 – 85.6) 80.0 (76.3 – 84.3) NS 
B1 (%) 24.4 (14.4 – 31.7) 20.0 (15.7 – 23.7) NS 
 
Absolute concentration of each glycome released from IgG4 
isolated from sera of patients with IgG4-related disease and 
healthy controls 
Galactosylation of IgG4 glycome 
Based on the number of galactoses, N-glycans released from IgG4 (IgG4 glycan) 
were divided into 4 groups: glycans without galactose (G0 IgG4 glycan), with 
monogalactose (G1 IgG4 glycan), with digalactose (G2 IgG4 glycan), and with 
trigalactose (G3 IgG4 glycan) (Fig 3). Absolute concentrations of IgG4 glycan in each 
group were compared between IgG4RD and healthy controls. As shown in Fig 4, 2 of 4 
G0 IgG4 glycans (33100, 35100) were unique in the IgG4 of IgG4RD. Significant 
elevations of G0 IgG4 glycan levels were observed in 2 of 4 G0 IgG4 glycans (33100, 
34100). Total G0 IgG4 glycan level was also significantly increased in IgG4RD compared 
with healthy controls.  
 
 
 Fig 3. Structures of agalactosylated (G0), monogalactosylated (G1), digalactosylated 
(G2), and trigalactosylated (G3) glycans released from IgG4 isolated from the sera 
of patients with IgG4RD and healthy controls. GlcNAc: N-Acetylglucosamine, 
GalNAc: N-Acetylgalactosamine. 
 
 
 
 
 
 Fig 4. Comparison of absolute concentrations of IgG4 G0 glycans between IgG4RD 
and healthy controls. Data are shown as box plots. The boxes indicate the upper and 
lower interquartile range (IQR), the lines within the boxes indicate the median, and the 
whiskers indicate the minimum and maximum IQR. Each dot represents an individual 
sample. Statistical analysis was performed using the Mann-Whitney U-test. 
 
Regarding G1 IgG4 glycans, there was no significant difference in total G1 IgG4 
glycan between IgG4RD and healthy controls, although 3 of 7 G1 IgG4 glycans (44110, 
45100, 45110) were significantly increased in IgG4RD compared with healthy controls 
(Fig 5). 
 
 
 Fig 5. Comparison of absolute concentration of IgG4 G1 glycans between IgG4RD 
and healthy controls. Data are shown as box plots. The boxes indicate the upper and 
lower interquartile range (IQR), the lines within the boxes indicate the median, and the 
whiskers indicate the minimum and maximum IQR. Each dot represents an individual 
sample. Statistical analysis was performed using the Mann-Whitney U-test. 
 
Regarding G2 IgG4 glycans, there was no significant difference in total G2 IgG4 
glycan between IgG4RD and healthy controls, although 4 of 10 G2 IgG4 glycans (55110, 
54120, 55120, 55020) were significantly increased in IgG4RD compared with healthy 
controls (Fig 6). 
 
 Fig 6. Comparison of absolute concentration of IgG4 G2 glycans between IgG4RD 
and healthy controls. Data are shown as box plots. The boxes indicate the upper and 
lower interquartile range (IQR), the lines within the boxes indicate the median, and the 
whiskers indicate the minimum and maximum IQR. Each dot represents an individual 
sample. Statistical analysis was performed using the Mann-Whitney U-test. 
 
As shown in Fig 7, although present at low concentrations, G3 IgG4 glycans 
(65110, 65120) were unique in IgG4RD. We did not perform statistical analysis for G3 
IgG4 glycans because of the small number of samples. 
 
 
 Fig 7. Comparison of absolute concentration of IgG4 G3 glycans between IgG4RD 
and healthy controls. Data are shown as box plots. The boxes indicate the upper and 
lower interquartile range (IQR), the lines within the boxes indicate the median, and the 
whiskers indicate the minimum and maximum IQR. Each dot represents an individual 
sample. Statistical analysis was not performed. 
 
Fucosylation of IgG4 glycan 
 Based on the number of fucoses, IgG4 glycans were divided into 2 groups: 
glycans without fucose (F0 IgG4 glycan) and with fucose (F1 IgG4 glycan) (Fig 8). As 
shown in Fig 9, F1 IgG4 glycan levels were increased in IgG4RD compared with healthy 
controls. However, there was no significant difference in the concentration of F0 glycans 
between IgG4RD and healthy controls. 
Fig 8. Structures of afucosylated (F0) and fucosylated (F1) glycans released from 
IgG4 isolated from the sera of patients with IgG4RD and healthy controls. GlcNAc: 
N-Acetylglucosamine, GalNAc: N-Acetylgalactosamine. 
 
 
 
 
 
 
 
 Fig 9. Comparison of absolute concentration of IgG4 F0 and F1 glycans between 
IgG4RD and healthy controls. Data are shown as box plots. The boxes indicate the 
upper and lower interquartile range (IQR), the lines within the boxes indicate the median, 
and the whiskers indicate the minimum and maximum IQR. Each dot represents an 
individual sample. Statistical analysis was performed using the Mann-Whitney U-test. 
 
Sialylation of IgG4 glycan 
 Based on the number of sialic acids, glycans detected in IgG4 were divided into 
3 groups: glycans without sialic acid (S0 IgG4 glycan), with 1 sialic acid (S1 IgG4 glycan), 
and with 2 sialic acids (S2 IgG4 glycan) (Fig 10). As shown in Fig 11, concentrations of 
S1 glycan were significantly elevated in IgG4RD compared with healthy controls. There 
were no significant differences in the concentrations of S0 and S2 IgG4 glycans between 
IgG4RD and healthy controls. 
 
 
Fig 10. Structures of asialylated (S0), monosialylated (S1), and disialylated (S2) 
glycans released from IgG4 isolated from the sera of patients with IgG4RD and 
healthy controls. GlcNAc: N-Acetylglucosamine, GalNAc: N-Acetylgalactosamine. 
 
 
 
 
 Fig 11. Comparison of absolute concentration of IgG4 S0, S1, and S2 glycans 
between IgG4RD and healthy controls. Data are shown as box plots. The boxes indicate 
the upper and lower interquartile range (IQR), the lines within the boxes indicate the 
median, and the whiskers indicate the minimum and maximum IQR. Each dot represents 
an individual sample. Statistical analysis was performed using the Mann-Whitney U-test. 
 
The relationship between manifestations of IgG4RD and IgG4 
glycan composition 
IgG4 glycan level was compared between patients with and without 
hypocomplementemia and for individual organ involvement (kidney, pancreas, lymph 
node) for galactosylation, fucosylation, and sialyation in IgG4RD. As shown in Table 3, 
there was a significant difference in F0 IgG4 glycans in IgG4RD with 
hypocomplementemia compared with those without hypocomplementemia. However, no 
significant differences in the galactosylation, fucosylation, and sialyation of IgG4 glycans 
were observed when IgG4RD with and without other individual organ involvement 
(kidney, pancreas, lymph node) were compared (Tables 4, 5, 6).  
 
Table 3. Comparison of the percentage and concentration of each IgG4 N-glycan 
between patients with IgG4-related disease with or without hypocomplementemia. 
 Hypocomplementemia (+) 
Patients 1 – 7 (n = 7) 
Median (range) 
Hypocomplementemia (−) 
Patients 8 – 12 (n = 5) 
Median (range) 
 
p value 
G0 (%) 36.1 (30.7 – 44.7) 36.6 (32.8 – 48.2) 0.876 
G0 (pmol/mg) 7204.8 (5322.8 – 7817.3) 5641.9 (4039.6 – 9210.5) 0.432 
G1 (%) 23.8 (22.5 – 24.3) 24.7 (21.6 – 27.2) 0.530 
G1 (pmol/mg) 4048.8 (3694.5 – 5036.2) 3434.9 (2724.5 – 6065.8) 0.343 
G2 (%) 39.3 (32.2 – 45.5) 37.5 (27.7 – 45.5) 0.343 
G2 (pmol/mg) 6201.3 (5542.9 – 9337.7) 4283.0 (3505.8 – 12763.2) 0.202 
G3 (%) 0.5 (0.0 – 1.1) 0.5 (0.0 – 0.7) 0.876 
G3 (pmol/mg) 74.7 (0.0 – 251.2) 64.0 (0.0 – 102.5) 0.755 
F0 (%) 3.5 (2.0 – 4.4) 6.5 (2.8 – 9.6) 0.030 
F0 (pmol/mg) 626.8 (394.8 – 824.4) 784.2 (722.6 – 1537.1) 0.030 
F1 (%) 96.5 (95.6 – 98.0) 93.5 (90.4 – 97.2) 0.030 
F1 (pmol/mg) 16,583.9 (14,760.6 – 21,205.5) 13,592.5 (10,324.5 – 27,255.3) 0.106 
S0 (%) 61.0 (52.8 – 64.8) 63.5 (55.7 – 69.7) 0.343 
S0 (pmol/mg) 10,824.6 (8952.8 – 12,251.5) 9343.9 (7009.4 – 15,631.6) 0.268 
S1 (%) 23.7 (21.1 – 26.1) 22.0 (19.5 – 27.5) 0.530 
S1 (pmol/mg) 3854.4 (3600.0 – 5552.0) 2835.0 (2432.1 – 7002.6) 0.343 
S2 (%) 15.4 (13.7 – 21.2) 14.0 (10.7 – 19.3) 0.202 
S2 (pmol/mg) 2622.0 (2412.5 – 4374.0) 1930.0 (1358.1 – 5405.3) 0.106 
Table 4. Comparison of the percentage and concentration of each IgG4 N-glycan 
between patients with IgG4-related disease with or without autoimmune 
pancreatitis. 
 
 Autoimmune pancreatitis (+) 
n = 4 
Median (range) 
Autoimmune pancreatitis (−) 
n = 8 
Median (range) 
 
p value 
G0 (%) 35.8 (35.09 – 44.7) 37.3 (30.7 – 48.2) NS 
G0 (pmol/mg) 5458.4 (4039.6 – 7698.2) 7079.9 (5641.9 – 9210.5) NS 
G1 (%) 24.5 (22.5 – 27.0) 23.3 (21.6 – 27.2) NS 
G1 (pmol/mg) 3786.5 (2724.5 – 4318.8) 4328.0 (3240.0 – 6065.8) NS 
G2 (%) 38.1 (32.2 – 40.6) 38.5 (27.7 – 45.5) NS 
G2 (pmol/mg) 5765.3 (4283.5 – 6157.5) 6750.1 (3505.8 – 12763.2) NS 
G3 (%) 0.3 (0 – 0.5) 0.5 (0 – 1.1) NS 
G3 (pmol/mg) 40.9 (0 – 91.1) 69.3 (0 – 251.2) NS 
F0 (%) 5.1 (2.7 – 9.6) 3.6 (2.0 – 6.5) NS 
F0 (pmol/mg) 674.7 (414.2 – 1537.1) 735.0 (394.8 – 942.5) NS 
F1 (%) 94.9 (90.4 – 97.3) 96.4 (93.5 – 98.0) NS 
F1 (pmol/mg) 14602.9 (10324.5 – 16583.9) 17751.7 (11901.2 – 27255.3) NS 
S0 (%) 61.2 (58.5 – 64.8) 61.8 (52.8 – 69.7) NS 
S0 (pmol/mg) 9148.3 (7009.4 – 11160.7) 10737.9 (8817.4 – 15631.6) NS 
S1 (%) 22.9 (21.1 – 27.5) 23.3 (19.5 – 26.1) NS 
S1 (pmol/mg) 3618.8 (2432.1 – 4393.2) 4157.1 (2470.9 – 7002.6) NS 
S2 (%) 14.3 (14.0 – 17.3) 15.0 (10.7 – 21.2) NS 
S2 (pmol/mg) 2328.8 (1605.7 – 2622.0) 2565.0 (1358.1 – 5405.3) NS 
 
 
 
 
Table 5. Comparison of the percentage and concentration in each IgG4 N-glycan 
between patients with IgG4-related disease with or without kidney disease. 
 
 Kidney disease (+) 
n = 6 
Median (range) 
Kidney disease (−) 
n = 6 
Median (range) 
 
p value 
G0 (%) 39.3 (30.7 – 48.2) 36.0 (35.0 – 44.6) NS 
G0 (pmol/mg) 7079.9 (5702.5 – 9210.5) 5617.9 (4039.6 – 7817.3) NS 
G1 (%) 22.6 (21.6 – 24.1) 24.5 (22.9 – 27.2) NS 
G1 (pmol/mg) 3963.7 (3240.0 – 6065.8) 4006.6 (2724.5 – 5036.2) NS 
G2 (%) 36.5 (28.6 – 45.5) 38.2 (27.2 – 40.6) NS 
G2 (pmol/mg) 5963.8 (4132.5 – 12763.2) 6072.6 (3505.8 – 8925.2) NS 
G3 (%) 0.5 (0.0 – 1.0) 0.3 (0.0 – 1.1) NS 
G3 (pmol/mg) 82.9 (0.0 – 198.4) 32.0 (0.0 – 251.2) NS 
F0 (%) 3.6 (2.6 – 6.5) 4.8 (2.0 – 9.6) NS 
F0 (pmol/mg) 710.4 (448.8 – 942.5) 734.0 (394.8 – 1537.1) NS 
F1 (%) 96.4 (93.5 – 97.4) 95.2 (90.4 – 98.0) NS 
F1 (pmol/mg) 16,557.6 (13,592.5 – 27,255.3) 14602.9 (10,324.5 – 21,205.5) NS 
S0 (%) 61.8 (52.8 – 67.2) 61.1 (54.9 – 69.7) NS 
S0 (pmol/mg) 10,737.9 (9620.3 – 15,631.6) 9148.3 (7009.4 – 12,251.5) NS 
S1 (%) 23.2 (19.5 – 26.1) 23.4 (19.5 – 27.5) NS 
S1 (pmol/mg) 3793.7 (2835.0 – 7002.6) 3996.6 (2432.1 – 5552.0) NS 
S2 (%) 15.0 (13.3 – 21.2) 14.3 (10.7 – 19.9) NS 
S2 (pmol/mg) 2452.4 (1930.0 – 5405.3) 2433.6 (1358.1 – 4374.0) NS 
 
 
 
 
Table 6. Comparison of the percentage and concentration in each IgG4 N-glycan 
between patients with IgG4-related disease with or without lymphadenopathy. 
 
 Lymphadenopathy (+) 
n = 7 
Median (range) 
Lymphadenopathy (−) 
n = 5 
Median (range) 
 
p value 
G0 (%) 36.1 (32.8 – 48.2) 36.4 (30.7 – 44.7) NS 
G0 (pmol/mg) 7204.8 (5322.8 – 9210.5) 5641.9 (4039.6 – 7698.2) NS 
G1 (%) 23.8 (21.6 – 24.3) 24.7 (22.5 – 27.2) NS 
G1 (pmol/mg) 4048.8 (3240.0 – 6065.8) 3878.6 (2724.5 – 4667.2.2) NS 
G2 (%) 39.3 (28.6 – 45.5) 37.5 (27.7 – 45.5) NS 
G2 (pmol/mg) 6201.3 (4132.5 – 12763.2) 5542.9 (3505.8 – 9337.7) NS 
G3 (%) 0 (0.0 – 1.1) 0.5 (0.0 – 1.0) NS 
G3 (pmol/mg) 0 (0.0 – 251.2) 81.7 (0.0 – 198.4) NS 
F0 (%) 2.8 (2.0 – 6.5) 5.9 (3.5 – 9.6) NS 
F0 (pmol/mg) 696.2 (394.8 – 942.5) 724.6 (626.8 – 1537.1) NS 
F1 (%) 97.2 (93.5 – 98.0) 94.1 (90.4 – 96.5) NS 
F1 (pmol/mg) 16,531.2 (13,592.5 – 27,255.3) 14,445.1 (10,324.5 – 19,782.0) NS 
S0 (%) 61.0 (54.9 – 67.2) 63.5 (52.8 – 69.7) NS 
S0 (pmol/mg) 10,651.2 (8952.8 – 15,631.6) 9343.9 (7009.4 – 11,160.7) NS 
S1 (%) 23.7 (19.5 – 25.2) 22.0 (19.5 – 27.5) NS 
S1 (pmol/mg) 3854.4 (2835.0 – 7002.6) 3637.5 (2432.1 – 5342.6) NS 
S2 (%) 15.4 (13.3 – 19.9) 14.0 (10.7 – 21.2) NS 
S2 (pmol/mg) 2622.0 (1930.0 – 5405.3) 2245.1 (1358.1 – 4339.3) NS 
 
 
 
 
Discussion 
This study reports significant increases of G0 IgG4 glycan concentrations in 
IgG4RD compared with healthy controls. Furthermore, F1 IgG4 glycan levels in IgG4RD 
were significantly increased in IgG4RD compared with healthy control. However, there 
were no significant differences in the levels of sialic acid or IgG4 glycan with bisecting 
arm between IgG4RD and healthy controls. Furthermore, we observed a significant 
decrease in F0 IgG4 glycans in IgG4RD with hypocomplementemia compared with those 
without hypocomplementemia, although the difference was small. There were no 
significant differences in the galactosylation and sialyation of IgG4 glycans between 
IgG4RD with and without hypocomplementemia. Regarding the individual organ 
involvement of IgG4RD (kidney, pancreas, lymph node), there were no significant 
differences in the galactosylation, fucosylation, and sialyation of IgG4 glycans between 
patients with and without each organ involvement.  
Recent studies strongly suggest that G0 glycans have proinflammatory nature[36, 
37, 42]. For example, IgGs with G0 glycans increased their affinity for FcγRIII, an 
activating FcγR. Although we observed an increase of G0 IgG4 glycans in patients with 
IgG4RD, and the proinflammatory nature of G0 glycans has been reported in a number 
of inflammatory diseases, it is not clear whether agalactosylated IgG4 is involved in the 
pathogenesis of IgG4RD because IgG4 has a low binding ability to FcγR. Furthermore, 
recent studies suggest that IgG4 has an anti-inflammatory rather than proinflammatory 
role.  
IgG subclasses other than IgG4 have proinflammatory properties that induce 
activation of the complement system as well as stimulating phagocytic or cytotoxic 
reactions. Unlike other IgG subclasses, IgG4 does not have the same proinflammatory 
properties, because IgG4 does not bind to C1q compared with FcγRI, RII, and RIIII[43]. 
Furthermore, IgG4 can exchange half its molecules resulting in the formation of chimeric 
antibodies with two different binding specificities, which are monovalent and unable to 
cross-link identical antigens to form ICs[44-46]. Therefore, IgG4 is presumed to have an 
anti-inflammatory rather than a proinflammatory role.  
 However, although IgG4 has anti-inflammatory properties, it does not mean that 
IgG4 is not pathogenic. Several reports showed that IgG4 autoantibodies were implicated 
in the pathogenesis of autoimmune diseases without requiring complement or other 
immune components. Huijhers et al reported that IgG4 autoantibodies to muscle-specific 
kinase cause myasthenia gravis by inhibiting the binding between muscle specific kinase 
and lipoprotein receptor-related protein[47, 48]. In pemphigus, IgG4 anti-desmoglein 
antibodies directly disrupt the epithelial layer and cause blister formation without 
complement activation or antibody-dependent cell-mediated cytotoxicity. Furthermore, 
IgG4 antibodies that recognize disintegrin-like and metalloproteinase with 
thrombospondin type 1 motifs 13 (ADAMTS13) are involved in the pathogenesis of 
thrombotic thrombocytopenic purpura[49-51]. Regarding IgG4RD, autoantibodies to 
putative antigens have been reported in patients with IgG4-related autoimmune 
pancreatitis and sialoadenitis. However, these autoantibodies have also been reported in 
other autoimmune diseases indicating a lack of disease-specificity for IgG4RD[52]. 
Currently, the pathogenic role of these autoantibodies has not been proven. 
 Elevated levels of G0 IgG were reported in the serum of patients with 
granulomatosis with polyangiitis (GPA, formerly named Wegener’s granulomatosis)[29]. 
Interestingly, 31% of biopsy specimens showed increased IgG4-positive cells in patients 
with GPA, thus GPA may mimic IgG4RD histologically[53]. Furthermore, in patients 
with GPA, IgG4 antibodies were reported to play a role in its pathogenesis. Holland et al. 
reported that IgG4 proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA) 
isolated from the sera of GPA patients activated neutrophils resulting in the production of 
superoxide. As the activity of stimulating neutrophils was independent of the neutrophil 
expression of FcγRI, this suggested that PR3-ANCA IgG4 antibodies activated 
neutrophils through FcγRIIa and FcγRIIIb[54]. Furthermore, Hussain et al. showed that 
monoclonal IgG4 anti PR3 antibodies induced the dose-dependent release of superoxide 
from neutrophils, as well as neutrophil degranulation and adhesion[55]. These reports 
suggest that IgG4 anti-PR3 may participate in the pathogenesis of vasculitis in GPA by 
stimulating neutrophils to induce a proinflammatory response. Taken together, G0-IgG4 
in patients with IgG4RD may participate in the pathogenesis of IgG4RD by the same 
mechanism as GPA, whereby neutrophils are stimulated followed by the induction of 
proinflammatory responses. 
 In this study, we observed a significant increase in F1 glycan concentration. 
Recently, Gornik et al. reported the increased level of serum IgG with F1 glycan in 
patients with RA[56]. Furthermore, Sjöwall et al. showed that patients with SLE had a 
significant increased exposure to fucosyl residues of complexed IgG in their serum[57]. 
Although it is unclear whether fucosylated IgG participates in the pathogenesis of these 
diseases, Sjöwall et al. hypothesized that highly fucosylated site of complexed IgG 
molecules may facilitate their uptake by binding to lectin receptors on the phagocyte 
surface to induce chronic inflammation. Further study on the pathogenic role of F1 IgG4 
glycans in patients with IgG4RD is required. 
 In this study, although there were no significant differences, the absolute 
concentration of G1, G2, and F0 glycans tended to be higher in IgG4RD than in healthy 
controls; thus, the total concentrations of all IgG4 glycans were increased in IgG4RD. As 
a result, the percentages of G0 as well as F1 glycans were lower and there was no 
significant difference between IgG4RD and healthy controls. Thus, the increase in total 
IgG4 glycans might be caused by increased amounts of Fab glycans. Because we used 
whole IgG4 as a sample, we detected N-glycans including the Fc and Fab portion of IgG4. 
Recent studies revealed that between 15%–25% of the total IgG glycome originates from 
Fab[58, 59], and that Fab-linked glycans have less core fucose, and more galactose and 
sialic acid compared with Fc-linked glycans[60-62]. Therefore, we think that an increase 
in the extent of Fab glycosylation might explain the lack of a significant difference in the 
proportion of IgG4 G0 glycans as well as F1 glycans in the total glycome of IgG4RD. 
Furthermore, compared with Fc glycan, Fab glycan is highly sialylated, and S1 glycan is 
the most abundant compared with S0 and S2 glycans[62]. Therefore, an increase in the 
extent of Fab glycosylation might affect the significantly elevated level of S1IgG4 glycan 
in IgG4RD compared with healthy controls, despite no significant changes in S0 and 
S2IgG4 glycans. 
 Recent studies show that agalactosylated IgG acts as an epitope for complement-
activating mannose-binding lectins resulting in activation of the lectin complement 
pathway[37]. Furthermore, in addition to activation of the lectin complement pathway, 
IgGs with G0 glycans also activate the classical and alternative complement 
pathways[63]. Therefore, we expected that hypogalactosylated IgG4 may contribute to 
hypocomplementemia in patients with IgG4RD. However, we did not observe significant 
differences in the galactosylation and sialyation of IgG4 glycans between IgG4RD with 
and without hypocomplementemia. Instead, we observed significant differences in the 
fucosylation of IgG4 glycans between IgG4RD with and without hypocomplementemia, 
although the difference was small. In general, afucosylated IgG abrogates binding C1q 
and therefore the antibody’s capacity to activate the complement system. Interestingly, a 
recent study showed that exposure to fucosyl residues on circulating IgG immune 
complexes was significantly correlated with the consumption of serum C3 in patients with 
SLE. However, IgG4 does not generally bind to C1q and does not activate the 
complement pathway. One possibility is that IgG4 isolated from IgG4RD with 
hypocomplementemia binds to C1q and is associated with the consumption of serum C3. 
Another possibility is that decreased levels of IgG4 F0 glycans and the increased tendency 
of IgG4 F1 glycans did not reflect complement activation directly, but rather chronic 
inflammation caused by complement activation indirectly. Further study is needed to 
determine the contribution of the IgG4 glycome to the mechanism of complement 
activation in IgG4RD with hypocomplementemia. 
Regarding the individual organ involvement of IgG4RD (kidney, pancreas, 
lymph node), there were no significant differences in the galactosylation, fucosylation, 
and sialyation of IgG4 glycans between patients with and without each organ involvement, 
which may suggest that the altered glycome of IgG4 is not related to the differences 
observed for individual organ involvement. 
Although the elevation of agalactosylated IgG levels are associated with several 
inflammatory and autoimmune diseases, the cause of the increase is not well understood. 
One possibility might be that reduced B-cell galactosyltransferase activity leads to lower 
galactosylation. Axford et al reported an association between reduced 
galactosyltransferase activity and serum agalactosylated IgG level in RA[64, 65]. Another 
possibility is that microenvironmental factors present during the differentiation of B cells 
to antibody-secreting cells might influence the glycosylation of IgG. Recent studies 
reported that the microenvironmental factors CpG oligodeoxynucleotide and interleukin-
21 increased Fc-linked galactosylation and reduced bisecting N-acetylglucosamine levels, 
whereas all-trans retinoic acid (a natural metabolite of vitamin A) significantly decreased 
galactosylation and sialylation levels[66-68]. 
 This study had several limitations. First, the numbers of patients and controls 
were relatively small because of our research budget. Second, it was impossible to 
differentiate N-glycans released from the Fab and Fc portions of IgG4. We used whole 
IgG4 as samples; therefore, we detected N-glycans from the Fc portion and the Fab 
portion of IgG4. Finally, because the number of IgG4RD patients and healthy controls 
were different, their age and gender were not matched. The proportion of agalactosylated 
IgG was reported to increase with age[69]. Although the proportion (%) of 
agalactosylated IgG between IgG4RD and healthy controls was not significantly different 
in this study, we cannot exclude the possibility that increased levels of G0 IgG4 glycans 
may be related to aging.  
Although we observed changes in IgG4 glycosylation isolated from the sera of 
patients with IgG4RD compared with healthy controls, it is not clear whether the 
increased IgG4 is the cause or a consequence of the inflammatory reactions associated 
with IgG4RD. Further studies of IgG4RD are needed to clarify the mechanism of IgG4 
production and the role of IgG4 in the pathogenesis of IgG4RD. 
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